<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160796</url>
  </required_header>
  <id_info>
    <org_study_id>PREVA</org_study_id>
    <nct_id>NCT01160796</nct_id>
  </id_info>
  <brief_title>Lcr35® for Bacterial Vaginosis Prevention</brief_title>
  <official_title>Study of the Efficacy and Safety of Treatment With Total Freeze-dried Culture of Lactobacillus Casei Var. Rhamnosus (Lcr35®) Administered Intravaginally in the Prevention of Bacterial Vaginosis. Randomized, Phase III, Multi-centre, Double-blind, Placebo-controlled Superiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Lyocentre</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Lyocentre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a national, multi-centre, randomized, double-blind placebo-controlled, phase III&#xD;
      superiority trial.&#xD;
&#xD;
      The main objective of the trial is to assess the efficacy of Lcr35® by comparing the mean&#xD;
      time before the onset of the first clinical recurrence confirmed by laboratory tests in&#xD;
      patients with bacterial vaginosis treated with Lcr35® versus placebo.&#xD;
&#xD;
      Patients with bacterial vaginosis will be enroll by private gynecologists. Each patient will&#xD;
      receive a treatment for the initial episode(Metronidazole)and a treatment to prevent the&#xD;
      recurrence of bacterial vaginosis (Lcr35®).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean time before the onset of first clinical recurrence confirmed by laboratory tests</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">352</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>Lcr35®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1x14-day course of treatment during 4 cycles</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lcr35®</intervention_name>
    <description>1x14-day course of treatment during 4 cycles</description>
    <arm_group_label>Lcr35®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient presenting with a symptomatic vaginosis characterised by the presence of the&#xD;
             following 3 clinical criteria (among the 4 Amsel criteria) at V1:&#xD;
&#xD;
               -  greyish uniform vaginal discharge,&#xD;
&#xD;
               -  characteristic &quot;rotten fish&quot; smell caused by the spontaneous release of amine or&#xD;
                  during the potassium test or &quot;sniff test&quot;,&#xD;
&#xD;
               -  vaginal pH greater than 4.5.&#xD;
&#xD;
          -  Patient with a Nugent score ≥ 7 (using the sample taken at V1).&#xD;
&#xD;
          -  Patient clinically cured (none of the 3 Amsel criteria) after a 7-day course of&#xD;
             Metronidazole (Flagyl®) Female.&#xD;
&#xD;
          -  Patient over 18 years of age.&#xD;
&#xD;
          -  For women with childbearing potential:&#xD;
&#xD;
               -  negative urine pregnancy test,&#xD;
&#xD;
               -  use of a contraceptive method deemed effective by the Investigator (excluding&#xD;
                  spermicides).&#xD;
&#xD;
          -  Patient having received information and voluntarily signed a written Informed Consent&#xD;
             Form.&#xD;
&#xD;
          -  Patient covered by a national insurance scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of a yeast infection that is bacterial (other than vaginosis) or viral in&#xD;
             origin presumed or proven to be gynaecologically-linked, whether or not treated within&#xD;
             the month preceding inclusion or present at the time of inclusion.&#xD;
&#xD;
          -  Presence of an existing gynaecological infection that may interfere with the&#xD;
             assessment of the trial treatment(fibroma, severe dysplasia of the cervix or in situ&#xD;
             carcinoma, invasive carcinoma, intra-epithelial cervical neoplasia, squamous&#xD;
             intra-epithelial lesions etc.)&#xD;
&#xD;
          -  Antibiotics or antifungals taken by general route during the month preceding the&#xD;
             screening visit, excluding treatment for an earlier episode of vaginosis.&#xD;
&#xD;
          -  Use of probiotics in the month preceding the screening visit, excluding treatment for&#xD;
             an earlier episode of vaginosis.&#xD;
&#xD;
          -  Use of intravaginal antiseptics in the month preceding the screening visit, excluding&#xD;
             treatment for an earlier episode of vaginosis.&#xD;
&#xD;
          -  Use of prebiotics (acidifiers) during the two weeks preceding the screening visit.&#xD;
&#xD;
          -  Use of products containing topical oestrogens during the month preceding the screening&#xD;
             visit.&#xD;
&#xD;
          -  Allergy to one of the active ingredients or one of the excipients in the products.&#xD;
&#xD;
          -  patient in post-menopausal time&#xD;
&#xD;
          -  Patient unable to comply with the constraints of the Protocol.&#xD;
&#xD;
          -  Breastfeeding patient.&#xD;
&#xD;
          -  Patient with menstrual bleeds lasting more than 12 days a month.&#xD;
&#xD;
          -  Patient having taken part in a clinical trial in the 3 months preceding inclusion in&#xD;
             the present Protocol.&#xD;
&#xD;
          -  Patient with a severe acute or chronic disease deemed by the Investigator to be&#xD;
             incompatible with participation in the trial, or a serious infection that is&#xD;
             life-threatening in the short term.&#xD;
&#xD;
          -  Immuno-suppressed patient.&#xD;
&#xD;
          -  Patient presenting with a previous illness which, according to the Investigator, is&#xD;
             likely to interfere with the results of the trial or expose the patient to an&#xD;
             additional risk.&#xD;
&#xD;
          -  Patient linguistically or mentally unable to understand and sign the Informed Consent&#xD;
             Form.&#xD;
&#xD;
          -  Patient deprived of her liberty by order of the Courts or civil authorities or subject&#xD;
             to a guardianship order.&#xD;
&#xD;
          -  Patient likely not to comply with treatment.&#xD;
&#xD;
          -  Patient unable to be contacted in the case of an emergency.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lyocentre</name>
      <address>
        <city>Aurillac</city>
        <zip>15000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>March 24, 2016</last_update_submitted>
  <last_update_submitted_qc>March 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

